Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019-2021.

ABSTRACT:

Introduction

Describe real-world treatment of osteoporosis and romosozumab treatment patterns in Japan.

Materials and methods

Data for patients initiating romosozumab or other antiosteoporotic medications between March 01, 2018, and May 31, 2022, were extracted from the Medical Data Vision (MDV) and Japan Medical Data Center (JMDC) databases. Patients were categorized into four cohorts: those who newly initiated romosozumab within the first (MDV: n = 4782; JMDC: n = 2578) or second (MDV: n = 3888; JMDC: n = 2446) year after launch and those who initiated teriparatide (TPTD; MDV: n = 14,576; JMDC: n = 8259) or non-TPTD antiosteoporotic medications within the first year of romosozumab launch (MDV: n = 352,142; JMDC: n = 185,785).

Results

Mean age, sex, baseline cardiova

SUBMITTER: Soen S 

PROVIDER: S-EPMC11631996 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature